版本:
中国

BRIEF-Biomarin Pharmaceutical says European commission approves Brineura as first treatment for CLN2 disease

June 1 Biomarin Pharmaceutical Inc:

* European commission approves Brineura (cerliponase alfa), the first treatment for cln2 disease, a form of batten disease and ultra-rare brain disorder in children

* Biomarin Pharmaceutical Inc says dosing administration includes all ages from birth Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐